ADRB2 and asthma: Furthermore, β2AR agonists that have been used for many years in the therapy of humans, e.g. as bronchodilators in patients with asthma or chronic obstructive pulmonary disease, should be reassessed using various native test systems, as there is a potential to improve already existing therapies, particularly by minimizing unwanted effects.